Hepatic Mitochondria and Insulin Resistance in Fatty Liver and Type 2 Diabetes

脂肪肝和 2 型糖尿病中的肝线粒体和胰岛素抵抗

• 批准号: 8402120
• 负责人: RANDY SCOTT RECTOR
• 金额: --
• 依托单位: HARRY S. TRUMAN MEMORIAL VA HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8402120
• 关键词: Adult; Affect; Age; Behavior Therapy; Body Weight decreased; Caloric Restriction; Chronic; Cirrhosis; Combined Modality Therapy; Development; Diabetes Mellitus; Diet; Disease; Effectiveness; Euglycemic Clamping; Exercise; Fatty Liver; Functional disorder; Future; General Population; Glucose Clamp; Goals; Health Personnel; Health Professional; Healthcare Systems; Hepatic; High Prevalence; Human; Hyperglycemia; Hyperphagia; Hypoglycemia; Inbred OLETF Rats; Incidence; Individual; Insulin Resistance; Intervention; Lead; Link; Lipids; Liver; Liver Mitochondria; Liver diseases; Metformin; Mitochondria; Modeling; Morbidity - disease rate; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Oral; Pathogenesis; Patients; Peripheral; Pharmaceutical Preparations; Population; Prevalence; Resistance development; Rodent Model; Role; Scientist; Secondary to; Therapeutic; Transcriptional Regulation; Transplantation Conditioning; Veterans; Work; diabetic; glucose output; in vivo; insight; insulin sensitivity; liver transplantation; mitochondrial dysfunction; mortality; non-alcoholic fatty liver; novel; oxidation; prevent; public health relevance; sedentary; therapeutic target

DESCRIPTION (provided by applicant): Nonalcoholic fatty liver disease (NAFLD) is a chronic, progressive liver disease that affects 30% of all US adults. NAFLD is strongly linked to type 2 diabetes, with an estimated 80% of type 2 diabetics having NAFLD. Unfortunately, the Veteran population has a significantly higher prevalence of diabetes than the general population (20-25% vs. 6-8%), and, therefore, it would be expected to have a similarly higher prevalence of NAFLD. Because NAFLD leads to a significant number of patients with cirrhosis and need for liver transplantation, this condition is an important issue for the VA healthcare system. Despite the strong association between NAFLD and type 2 diabetes, a unifying pathophysiology remains poorly understood. The overall hypothesis of this proposal is that hepatic lipid intermediate/metabolite accumulation and hepatic insulin resistance develops due to hepatic mitochondrial dysfunction, which leads to dysregulated hepatic glucose output and ultimately development of type 2 diabetes. In addition, targeting hepatic mitochondrial dysfunction and hepatic insulin resistance with lifestyle modifications and/or pharmacological interventions will effectively treat NAFLD and type 2 diabetes. We will conduct studies in the Otsuka Long-Evans Tokushima Fatty (OLETF) rat, a well characterized rodent model of hyperphagia-induced obesity, NAFLD, and type 2 diabetes to examine the following specific aims. 1) Determine whether hepatic insulin resistance associated with NAFLD develops secondary to mitochondrial dysfunction and is a significant contributing factor in the development of type 2 diabetes. 2) Determine the effectiveness of daily exercise vs. caloric restriction (with and without metformin) in the treatment of NAFLD and type 2 diabetes. For Aim 1, OLETF rats will be studied at different ages throughout the spectrum of pre-insulin resistance, insulin resistance, and development of frank type 2 diabetes. For Aim 2, OLETF rats will be treated with exercise, caloric restriction, metformin, or combination therapies. The studies will employ in-vivo hyperinsulinemic-euglycemic clamps to assess systemic and hepatic insulin sensitivity and thorough examinations of hepatic mitochondrial function/content and lipid intermediate/metabolites accumulation. This project is extremely novel as it will examine the role of hepatic mitochondrial dysfunction and hepatic insulin resistance throughout the initiation, development, and progression of systemic insulin resistance and type 2 diabetes. In addition, it will comprehensively examine the effectiveness of lifestyle modifications and pharmacological interventions in the treatment of NAFLD and type 2 diabetes. These studies will provide future insight into reducing the incidence of type 2 diabetes and NAFLD in our Veteran population.

描述(由申请人提供)： 非酒精性脂肪性肝病(NAFLD)是一种慢性进行性肝病，影响30%的美国成年人。非酒精性脂肪肝与2型糖尿病密切相关，估计有80%的2型糖尿病患者患有非酒精性脂肪肝。不幸的是，退伍军人的糖尿病患病率明显高于普通人群(20%-25%对6%-8%)，因此，预计它的NAFLD患病率也会同样高。由于非酒精性脂肪肝导致大量的肝硬变患者需要肝移植，这种情况对退伍军人管理局的医疗系统来说是一个重要的问题。尽管NAFLD与2型糖尿病之间有很强的相关性，但统一的病理生理学仍然知之甚少。这一建议的总体假设是，肝脏线粒体功能障碍导致肝脏脂质中间/代谢物积聚和肝脏胰岛素抵抗，从而导致肝脏葡萄糖输出失调，最终发展为2型糖尿病。此外，针对肝脏线粒体功能障碍和肝脏胰岛素抵抗，通过改变生活方式和/或药物干预，将有效地治疗NAFLD和2型糖尿病。我们将在大冢Long-Evans Tokushima Fatty(OLETF)大鼠中进行研究，OLETF是一种典型的高吞噬诱导肥胖、NAFLD和2型糖尿病的啮齿动物模型，以检验以下特定目标。1)确定与NAFLD相关的肝脏胰岛素抵抗是否继发于线粒体功能障碍，并是2型糖尿病发生的重要因素。2)确定每日运动和热量限制(使用和不使用二甲双胍)在治疗NAFLD和2型糖尿病方面的有效性。对于目标1，将研究不同年龄的OLETF大鼠的胰岛素前期抵抗、胰岛素抵抗和弗兰克2型糖尿病的发展。对于目标2，OLETF大鼠将接受运动、热量限制、二甲双胍或联合治疗。这些研究将使用体内高胰岛素-正常血糖钳夹来评估全身和肝脏的胰岛素敏感性，并彻底检查肝脏线粒体的功能/含量和脂质中间/代谢物的积累。这个项目非常新颖，因为它将研究肝脏线粒体功能障碍和肝脏胰岛素抵抗在全身性胰岛素抵抗和2型糖尿病的发生、发展和进展中的作用。此外，它还将全面检查生活方式改变和药物干预在治疗非酒精性脂肪肝和2型糖尿病方面的有效性。这些研究将为减少我们退伍军人中2型糖尿病和非酒精性脂肪肝的发生率提供未来的见解。